• EDITORIAL POLICY
  • ABOUT US
PML Daily
  • Home
  • NEWS
    • Politics
    • Education
    • Regional
    • Africa
    • World
  • INVESTIGATIONS
    • National Archives
    • Special Reports
  • OpEd
  • BUSINESS
    • Agriculture
    • Tech
    • Finance
  • FEATURES
    • Health
    • Tours & Travel
    • Entertainment
    • Society
  • COLUMNISTS
    • The Suited Penguin
  • SPORT
  • Jobs
  • Magazines
No Result
View All Result
  • Home
  • NEWS
    • Politics
    • Education
    • Regional
    • Africa
    • World
  • INVESTIGATIONS
    • National Archives
    • Special Reports
  • OpEd
  • BUSINESS
    • Agriculture
    • Tech
    • Finance
  • FEATURES
    • Health
    • Tours & Travel
    • Entertainment
    • Society
  • COLUMNISTS
    • The Suited Penguin
  • SPORT
  • Jobs
  • Magazines
No Result
View All Result
PML Daily
No Result
View All Result
Home NEWS

BAT progresses COVID-19 candidate vaccine into Phase 1 human clinical trials

PETER SSENTI | PML Daily Correspondent by PETER SSENTI | PML Daily Correspondent
December 22, 2020
in NEWS
0 0
134
VIEWS
FacebookWhatsAppTwitter
Dr David O’Reilly, BAT’s Director of Scientific Research (PHOTO/File).

NAIROBI – British American Tobacco’s (BAT) US Bio-tech arm, Kentucky BioProcessing (KBP) today announced plans to commence a Phase I, first-time-in-human study of its COVID-19 vaccine candidate following approval of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA). Enrolment for the study is expected to begin shortly.

The COVID-19 vaccine candidate (KBP-COVID-19; NCT04473690) will become one of a number of potential vaccines to have progressed beyond pre-clinical testing. The study is designed to enroll a total of 180 healthy volunteers who will be divided into two age cohorts, age 18-49 and age 50-70. Each group will then be subdivided into low and high dose treatment groups (N~45) and randomised 2:1 to receive either the low dose (15 ?g KBP-COVID-19 vaccine + 0.5 mg adjuvant) or placebo, or high dose (45 ?g KBP-COVID-19 vaccine + 0.5 mg adjuvant) or placebo. Results from the study are expected mid-2021 and, if positive, would allow for continued progress into a Phase 2 study, subject to regulatory approval.

The candidate vaccine has been developed using KBP’s innovative fast-growing plant-based technology. This unique approach has a number of possible advantages, including the rapid production of the vaccine’s active ingredients in around 6-weeks, compared to several months using conventional methods.

The candidate vaccine also has the potential to be stable at room temperature, which could be a significant advantage for healthcare systems and public health networks worldwide. If successful, the speed of production of the active ingredients has the potential to reduce the time between identifying new viruses and strains, and vaccine development and deployment to those who need it.

KBP is conducting and recently completed enrolment for a Phase I clinical study of its quadrivalent (four-strain) influenza vaccine candidate (KBP-V001; NCT04439695), which uses the same nicotiana benthamiana plant-based technology platform.

Dr David O’Reilly, BAT’s Director of Scientific Research said: “Moving into human trials with both our COVID-19 and seasonal flu vaccine candidates is a significant milestone and reflects our considerable efforts to accelerate the development of our emerging biologicals portfolio. It is our unique plant-based vaccine technology, which acts as a fast, efficient host for the production of antigens for a variety of diseases, that has enabled us to make this progress and respond to the urgent global need for safe and effective treatments and vaccines.

With both vaccines reaching these important milestones, the science around tobacco plant-based vaccine development and the unique platform continue to gain momentum.

Beverley Spencer-Obatoyinbo, BAT Kenya’s Managing Director said: “This is part of our ongoing commitment to innovation and science, which are fundamental to our business. As a company committed to building A Better Tomorrow, we are proud to play our part in the global fight against this virus and – hopefully – we can contribute to the solution.”

Comments

Tags: British American TobaccoCOVID-19 candidate vaccineDr David O'Reillytop

Related Posts

More than 50 countries around the world have already adopted medicinal cannabis programmes (PHOTO/Courtesy).
BUSINESS

UN approves Marijuana usage

January 27, 2021
141
NUP's Regina Nakazzi Bakitte (PHOTO/Courtesy).
NEWS

NUP’s Nakazzi Bakitte wins Nansana Municipality mayoral seat

January 27, 2021
86
President Biden has targeted the elimination of billion-dollar oil and gas subsidies in the U.S. and called on other developed countries to do the same (PHOTO/Courtesy).
World

Biden moves to repeal Trump’s transgender military ban

January 26, 2021
73
Singer Bebe Cool and wife Zuena (PHOTO/Courtesy).
Society

Bebe, Zuena share pleasantries as they celebrate 19years of companionship

January 26, 2021
91
Singer Geosteady with wife (PHOTO/File).
Society

Geosteady ‘Hassan’s ex-lover tips broken hearts as singer denies ever being married

January 26, 2021
90
U.S Chief Justice John Roberts (R) and Ex-President Donald Trump (PHOTO/Courtesy).
World

U.S. Supreme Court chief justice not to preside over Trump’s impeachment trial

January 26, 2021
116

Advertisement






 

 

About

The PML Daily, published via www.pmldaily.com is a publication of Post Media Ltd, a professional Digital/New Media company in Uganda.

Follow us

KIU

  • EDITORIAL POLICY
  • ABOUT US

© 2020 PMLDAILY.COM

No Result
View All Result
  • Home
  • NEWS
    • Politics
    • Education
    • Regional
    • Africa
    • World
  • INVESTIGATIONS
    • National Archives
    • Special Reports
  • OpEd
  • BUSINESS
    • Agriculture
    • Tech
    • Finance
  • FEATURES
    • Health
    • Tours & Travel
    • Entertainment
    • Society
  • COLUMNISTS
    • The Suited Penguin
  • SPORT
  • Jobs
  • Magazines

© 2020 PMLDAILY.COM

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In